These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20977406)

  • 21. Images of the Month: Gastric Pneumatosis Due to Sevelamer-Mediated Necrosis.
    Amer S; Nguyen C; DePetris G
    Am J Gastroenterol; 2015 Jun; 110(6):799. PubMed ID: 26052763
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.
    Ketteler M; Rix M; Fan S; Pritchard N; Oestergaard O; Chasan-Taber S; Heaton J; Duggal A; Kalra PA
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1125-30. PubMed ID: 18450923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Education for dialysis patients lowers long-term phosphate levels and maintains health-related quality of life.
    Gardulf A; Pålsson M; Nicolay U;
    Clin Nephrol; 2011 Apr; 75(4):319-27. PubMed ID: 21426886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom.
    Bernard L; Mendelssohn D; Dunn E; Hutchison C; Grima DT
    J Med Econ; 2013; 16(1):1-9. PubMed ID: 22857538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Phosphate binders in chronic kidney disease: the positions of sevelamer].
    Fomin VV; Shilov EM; Svistunov AA; Milovanov IuS
    Ter Arkh; 2013; 85(6):96-9. PubMed ID: 23875200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.
    Brandenburg VM; Schlieper G; Heussen N; Holzmann S; Busch B; Evenepoel P; Vanholder R; Meijers B; Meert N; Fassbender WJ; Floege J; Jahnen-Dechent W; Ketteler M
    Nephrol Dial Transplant; 2010 Aug; 25(8):2672-9. PubMed ID: 20172849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sevelamer.
    Wrong O; Harland C
    Nephrol Dial Transplant; 2008 Jun; 23(6):2108; author reply 2101-2. PubMed ID: 18400812
    [No Abstract]   [Full Text] [Related]  

  • 28. The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders?
    Cozzolino M; Mazzaferro S; Brandenburg V
    Nephrol Dial Transplant; 2011 Feb; 26(2):402-7. PubMed ID: 21079194
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial.
    Suki WN;
    J Ren Nutr; 2008 Jan; 18(1):91-8. PubMed ID: 18089452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging effects of sevelamer in chronic kidney disease.
    Ikee R; Tsunoda M; Sasaki N; Sato N; Hashimoto N
    Kidney Blood Press Res; 2013; 37(1):24-32. PubMed ID: 23486088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
    Spatz C; Roe K; Lehman E; Verma N
    Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Either calcium carbonate or sevelamer decreases urinary oxalate excretion in chronic renal failure patients].
    Caravaca F; Ruiz AB; Escola JM; Hernández Gallego R; Cerezo I; Fernández N; Barroso S; Martín MV
    Nefrologia; 2007; 27(4):466-71. PubMed ID: 17944584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and utility of a multi-dimensional grid to assess individual mineral metabolism control in hemodialysis patients: A potential aid for therapeutic decision making?
    Morton AR; Murphy S; Hirsch D; Leblanc M; Barré P; Lok C; Hercz G; Hodsman A; Reslerova M; Levin A
    Hemodial Int; 2010 Apr; 14(2):200-10. PubMed ID: 20337745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of chronic renal failure rats and modification of the preparation protocol as a hyperphosphataemia model.
    Terai K; Mizukami K; Okada M
    Nephrology (Carlton); 2008 Apr; 13(2):139-46. PubMed ID: 18275502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of phosphate binding by sevelamer carbonate powder for oral suspension mixed in foods.
    Hanus M; Zhorov E; Brommage D; Plone M; Holmes-Farley SR
    Nephrol Nurs J; 2012; 39(3):239-43, 255. PubMed ID: 22866363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early initiation of phosphate lowering dietary therapy in non-dialysis chronic kidney disease: a critical review.
    Sigrist MK; Chiarelli G; Lim L; Levin A
    J Ren Care; 2009 Mar; 35 Suppl 1():71-8. PubMed ID: 19222735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacological and clinical profile of bixalomer (Kiklin(®) capsules): a new therapeutic agent for hyperphosphatemia].
    Taniguchi K; Kakuta H; Tomura Y; Kaku S; Uchida W
    Nihon Yakurigaku Zasshi; 2013 Jun; 141(6):333-7. PubMed ID: 23749074
    [No Abstract]   [Full Text] [Related]  

  • 38. Sevelamer treatment strategy in peritoneal dialysis patients: conventional dose does not make best use of resources.
    Chow KM; Szeto CC; Kwan BC; Leung CB; Li PK
    J Nephrol; 2007; 20(6):674-82. PubMed ID: 18046669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sevelamer carbonate. No better than sevelamer hydrochloride.
    Prescrire Int; 2010 Jun; 19(107):104-5. PubMed ID: 20738030
    [No Abstract]   [Full Text] [Related]  

  • 40. Sevelamer prescriptions after reporting of the Dialysis Clinical Outcomes Revisited (DCOR) trial findings: An analysis of 5,495 patients receiving maintenance dialysis in Ontario, Canada.
    Weir MA; Jain AK; Gomes T; Juurlink DN; Mamdani M; Li L; Garg AX
    Am J Kidney Dis; 2011 Feb; 57(2):357-9. PubMed ID: 21251552
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.